Farbod Nicholas Rahaghi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Artery | 17 | 2024 | 1927 | 3.060 |
Why?
|
Ventricular Dysfunction, Right | 8 | 2023 | 628 | 1.930 |
Why?
|
Pulmonary Embolism | 7 | 2023 | 2567 | 1.610 |
Why?
|
Pulmonary Veins | 5 | 2021 | 743 | 1.480 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 14 | 2024 | 3204 | 1.110 |
Why?
|
Tomography, X-Ray Computed | 20 | 2024 | 20570 | 0.980 |
Why?
|
Lung Diseases | 3 | 2021 | 1909 | 0.860 |
Why?
|
Hypertension, Pulmonary | 9 | 2024 | 1578 | 0.760 |
Why?
|
Schistosomiasis | 1 | 2021 | 65 | 0.730 |
Why?
|
Lung Diseases, Obstructive | 1 | 2021 | 308 | 0.730 |
Why?
|
Heart Ventricles | 5 | 2021 | 3807 | 0.730 |
Why?
|
Mediastinum | 1 | 2021 | 267 | 0.670 |
Why?
|
Ventricular Function | 2 | 2018 | 406 | 0.620 |
Why?
|
Phlebography | 1 | 2019 | 326 | 0.620 |
Why?
|
Thrombectomy | 1 | 2023 | 705 | 0.590 |
Why?
|
Therapy, Computer-Assisted | 1 | 2019 | 266 | 0.580 |
Why?
|
Thrombolytic Therapy | 3 | 2023 | 2064 | 0.560 |
Why?
|
Fibrinolytic Agents | 3 | 2023 | 2084 | 0.540 |
Why?
|
Cardiac Volume | 1 | 2017 | 197 | 0.530 |
Why?
|
Ultrasonography | 2 | 2019 | 5972 | 0.510 |
Why?
|
Vasodilation | 1 | 2019 | 962 | 0.500 |
Why?
|
Tomography, Emission-Computed | 1 | 2018 | 1122 | 0.500 |
Why?
|
Vasodilator Agents | 1 | 2019 | 973 | 0.500 |
Why?
|
Respiratory Function Tests | 6 | 2021 | 1682 | 0.480 |
Why?
|
Vascular Diseases | 2 | 2021 | 1161 | 0.470 |
Why?
|
Lung | 10 | 2024 | 10000 | 0.470 |
Why?
|
Pulmonary Emphysema | 4 | 2021 | 684 | 0.450 |
Why?
|
Heart | 3 | 2021 | 4404 | 0.400 |
Why?
|
Acute Disease | 5 | 2023 | 7237 | 0.400 |
Why?
|
Preoperative Period | 1 | 2014 | 551 | 0.390 |
Why?
|
Exercise Tolerance | 6 | 2024 | 836 | 0.390 |
Why?
|
Nitric Oxide | 1 | 2019 | 2135 | 0.360 |
Why?
|
Smoking | 5 | 2019 | 9053 | 0.360 |
Why?
|
Echocardiography | 3 | 2021 | 4989 | 0.320 |
Why?
|
Venous Thrombosis | 1 | 2018 | 1303 | 0.320 |
Why?
|
Hemodynamics | 2 | 2021 | 4159 | 0.310 |
Why?
|
Pneumonectomy | 1 | 2014 | 1119 | 0.280 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3530 | 0.270 |
Why?
|
Idiopathic Interstitial Pneumonias | 1 | 2024 | 24 | 0.230 |
Why?
|
Heart Diseases | 1 | 2017 | 2781 | 0.220 |
Why?
|
Forced Expiratory Volume | 5 | 2019 | 1814 | 0.210 |
Why?
|
Risk Assessment | 3 | 2021 | 23995 | 0.210 |
Why?
|
Bronchiectasis | 1 | 2022 | 139 | 0.180 |
Why?
|
Vascular Resistance | 2 | 2021 | 930 | 0.180 |
Why?
|
Humans | 44 | 2024 | 761504 | 0.180 |
Why?
|
Middle Aged | 23 | 2024 | 220895 | 0.180 |
Why?
|
Pulmonary Heart Disease | 1 | 2019 | 34 | 0.170 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2017 | 1050 | 0.170 |
Why?
|
Catheters | 1 | 2023 | 427 | 0.170 |
Why?
|
Aged | 19 | 2024 | 169289 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 3 | 2018 | 36426 | 0.160 |
Why?
|
Retrospective Studies | 10 | 2024 | 80636 | 0.160 |
Why?
|
Pulmonary Circulation | 3 | 2019 | 737 | 0.160 |
Why?
|
Male | 25 | 2024 | 360804 | 0.150 |
Why?
|
Atrial Function | 1 | 2018 | 99 | 0.150 |
Why?
|
Female | 25 | 2024 | 392644 | 0.150 |
Why?
|
Stroke Volume | 4 | 2019 | 5496 | 0.150 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6485 | 0.140 |
Why?
|
Aftercare | 1 | 2023 | 914 | 0.140 |
Why?
|
Administration, Inhalation | 1 | 2019 | 1157 | 0.140 |
Why?
|
Predictive Value of Tests | 3 | 2023 | 15266 | 0.130 |
Why?
|
Models, Economic | 1 | 2020 | 716 | 0.130 |
Why?
|
Lung Diseases, Interstitial | 1 | 2024 | 918 | 0.130 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20098 | 0.120 |
Why?
|
Disease Progression | 6 | 2021 | 13506 | 0.120 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15842 | 0.120 |
Why?
|
Bronchography | 1 | 2015 | 75 | 0.120 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2019 | 1222 | 0.120 |
Why?
|
Microcirculation | 1 | 2019 | 1273 | 0.120 |
Why?
|
Oxygen | 2 | 2023 | 4227 | 0.120 |
Why?
|
Angiography | 1 | 2019 | 1595 | 0.120 |
Why?
|
Blood Volume | 1 | 2015 | 547 | 0.110 |
Why?
|
Blood Glucose | 1 | 2008 | 6391 | 0.110 |
Why?
|
Myocardial Contraction | 1 | 2018 | 1515 | 0.100 |
Why?
|
Shock, Septic | 1 | 2019 | 768 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1113 | 0.100 |
Why?
|
Regression Analysis | 2 | 2019 | 6343 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2017 | 1241 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2019 | 9000 | 0.100 |
Why?
|
Postoperative Complications | 1 | 2014 | 15631 | 0.100 |
Why?
|
Cohort Studies | 5 | 2024 | 41487 | 0.100 |
Why?
|
Aorta | 1 | 2019 | 2042 | 0.100 |
Why?
|
Pulmonary Edema | 1 | 2014 | 409 | 0.090 |
Why?
|
Bronchi | 1 | 2015 | 845 | 0.090 |
Why?
|
Heart Failure | 3 | 2019 | 11669 | 0.090 |
Why?
|
Artifacts | 1 | 2019 | 1911 | 0.090 |
Why?
|
Patient Discharge | 1 | 2023 | 3443 | 0.090 |
Why?
|
Asthma | 2 | 2019 | 6234 | 0.090 |
Why?
|
Survival Rate | 2 | 2021 | 12725 | 0.080 |
Why?
|
Exercise Test | 3 | 2023 | 2127 | 0.080 |
Why?
|
Diabetes Mellitus | 1 | 2008 | 5840 | 0.080 |
Why?
|
Radiographic Image Enhancement | 1 | 2014 | 876 | 0.080 |
Why?
|
Trachea | 1 | 2015 | 1089 | 0.080 |
Why?
|
Endothelium, Vascular | 1 | 2021 | 4431 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 2 | 2019 | 4063 | 0.080 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39106 | 0.070 |
Why?
|
Prognosis | 3 | 2023 | 29625 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6346 | 0.070 |
Why?
|
Sepsis | 1 | 2019 | 2585 | 0.060 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2008 | 467 | 0.060 |
Why?
|
Vital Capacity | 2 | 2019 | 971 | 0.060 |
Why?
|
Adult | 8 | 2024 | 221177 | 0.060 |
Why?
|
Oxygen Consumption | 2 | 2022 | 1866 | 0.060 |
Why?
|
Organ Size | 2 | 2019 | 2254 | 0.060 |
Why?
|
Boston | 1 | 2016 | 9326 | 0.060 |
Why?
|
Electrocardiography | 1 | 2017 | 6377 | 0.050 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2024 | 273 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14666 | 0.050 |
Why?
|
Eating | 1 | 2008 | 1539 | 0.050 |
Why?
|
Myocardium | 1 | 2014 | 4726 | 0.050 |
Why?
|
Contrast Media | 1 | 2014 | 5311 | 0.050 |
Why?
|
Logistic Models | 3 | 2020 | 13255 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2022 | 469 | 0.040 |
Why?
|
Therapeutic Equipoise | 1 | 2019 | 28 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15732 | 0.040 |
Why?
|
Ventricular Function, Right | 1 | 2023 | 617 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14605 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13380 | 0.040 |
Why?
|
United States | 3 | 2021 | 72334 | 0.040 |
Why?
|
Motor Activity | 1 | 2008 | 2715 | 0.040 |
Why?
|
Pulmonary Gas Exchange | 1 | 2019 | 379 | 0.040 |
Why?
|
Pulmonary Ventilation | 1 | 2019 | 372 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2019 | 58976 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2022 | 12463 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2023 | 64680 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 12947 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2019 | 579 | 0.030 |
Why?
|
Maximal Midexpiratory Flow Rate | 1 | 2015 | 76 | 0.030 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 474 | 0.030 |
Why?
|
Resuscitation | 1 | 2019 | 673 | 0.030 |
Why?
|
Total Lung Capacity | 1 | 2015 | 149 | 0.030 |
Why?
|
Lung Volume Measurements | 1 | 2015 | 375 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 22170 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12059 | 0.030 |
Why?
|
Coronary Circulation | 1 | 2018 | 1569 | 0.020 |
Why?
|
Exercise | 2 | 2019 | 5890 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15500 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 9469 | 0.020 |
Why?
|
Internet | 1 | 2023 | 3092 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 22176 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3600 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 74206 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5871 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11121 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2901 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9318 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5492 | 0.020 |
Why?
|
Time Factors | 1 | 2008 | 39967 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10552 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9280 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8002 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4812 | 0.010 |
Why?
|
Prospective Studies | 2 | 2020 | 54425 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7967 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 14031 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 26125 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 59243 | 0.010 |
Why?
|